<DOC>
	<DOCNO>NCT01788371</DOCNO>
	<brief_summary>To explore antiviral effect nucleoside analogue late pregnancy safety antiviral drug fetus.To establish best therapy strategy pregnant woman high level HBV DNA .</brief_summary>
	<brief_title>Nucleoside Analogue Prevent Vertical Transmission Hepatitis B Virus</brief_title>
	<detailed_description>Telbivudine Lamivudine , preganancy category B medication , reduce HBV DNA normalize serum ALT chronic hepatitis B patient adverse effects.Two aspect drug use pregnancy evaluate prospectively study .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Viremia</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>HBeAg+CHB pregnant woman gestational age 28 week HBVDNA &gt; log10 copies/ml coinfection hepatitis A , C , D , E HIV evidence hepatocellular carcinoma decompensated liver disease significant comorbidity concurrent treatment immunemodulators , cytotoxic drug , steroid clinical sign threaten miscarriage early prenancy evidence fetal deformity ultrasound examination biological father child CHB</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>